A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis

Inclusion Criteria:

Part A and C:

• Overtly healthy as determined by medical evaluation

1. To qualify as Japanese for the purpose of this study, the participant must befirst generation Japanese, defined as the participant's biological parents andall of the participant's biological grandparents must be of exclusive Japanesedescent, and must have been born in Japan

2. To qualify as Chinese for the purpose of this study, the participant must be,at a minimum, third-generation Chinese, defined as all 4 of the participant'sbiological grandparents must be of exclusive Chinese descent and born in China

• Have a body mass index of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive

• Male participants who agree to use highly effective or effective methods ofcontraception and women not of childbearing potential may participate in part A andC

Part B:

• Participants who have a diagnosis of atopic dermatitis at least 12 months prior toscreening as defined by the American Academy of Dermatology

• Have a history, documented by a physician and/or investigator, of inadequateresponse to existing topical medications within 6 months preceding screening, orparticipants who failed systemic therapies intended to treat atopic dermatitis or ahistory of intolerance to topical therapy

• Have a body mass index of 18.0 to 38.0 kilograms per square meter (kg/m²), inclusive

• Male participants who agree to use highly effective or effective methods ofcontraception, women not of childbearing potential and women of childbearingpotential may participate in part B

Exclusion Criteria:

• Women who are pregnant and/or lactating

• Participants who have received live vaccine(s) (including attenuated live vaccines)or Bacillus Calmette- Guérin within 35 days of screening

• Have a history or presence of multiple or severe allergies or an anaphylacticreaction to prescription or nonprescription drugs

• Have a known history of diabetes

• Have fasting glucose level of ≥126 milligrams per deciliter (mg/dL) and glycatedhemoglobin ≥6.5 percent (%) and/or taking anti-diabetes medications at screening

• Have known history of osteoporosis